Obesity is a complex health issue with growing prevalence worldwide. It is also becoming more prevalent in the population of older adults (i.e., 65 years of age and older), affecting frequency and severity as well as other comorbidities, quality of life and consequently, life expectancy. In this article we review currently available data on pharmacotherapy of obesity in the population of older adults and its role in obesity management. Even though there is growing evidence, in particular in the general population, of favourable efficacy and safety profiles of glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide, and recently dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide, concise guidelines for older adults are not available to this day. We further discuss specific approaches to frequently represented phenotype of obesity in older adults, in particular sarcopenic obesity and rationale when to treat and how. In older adults with obesity there is a need for more drug trials focusing not only on weight loss, but also on geriatric endpoints including muscle mass preservation, bone quality and favourable fat distribution changes to get enough data for evidence-based recommendation on obesity treatment in this growing sub-population.

1st Faculty of Medicine Charles University Prague Czechia

Department of Diabetes and Endocrinology Tameside and Glossop Integrated Care NHS Foundation Trust and University of Manchester Ashton under Lyne UK

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czechia

Zobrazit více v PubMed

Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–25. PubMed

Grimm W, Becker HF. Obesity, sleep apnea syndrome, and rhythmogenic risk. Herz. 2006;31(3):213–8 (quiz 9). PubMed

Bastien M, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56(4):369–81. PubMed

Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 2023;15(2):485. PubMed PMC

Lega IC, Lipscombe LL. Review: diabetes, obesity, and cancer-pathophysiology and clinical implications. Endocr Rev. 2020;41(1):33–52. PubMed

Preston SH, Stokes A. Contribution of obesity to international differences in life expectancy. Am J Public Health. 2011;101(11):2137–43. PubMed PMC

Lung T, Jan S, Tan EJ, Killedar A, Hayes A. Impact of overweight, obesity and severe obesity on life expectancy of Australian adults. Int J Obes (Lond). 2019;43(4):782–9. PubMed

Stephenson J, Smith CM, Kearns B, Haywood A, Bissell P. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. BMC Public Health. 2021;21(1):1990. PubMed PMC

WHO WHO. Obesity. Feb. 21, 2022. https://www.who.int/health-topics/obesity. Accessed 9 Dec 2023.

Purnell JQ. Definitions, classification, and epidemiology of obesity. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth, MA: MDText.com, Inc; 2000. PubMed

Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–37. PubMed PMC

WHO. Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva; 8–11 December 2008.

(NAASO) NAAftSoO. Executive summary. Obes Res. 1998;6(S2):51S-210S.

Ceniccola GD, Castro MG, Piovacari SMF, Horie LM, Corrêa FG, Barrere APN, et al. Current technologies in body composition assessment: advantages and disadvantages. Nutrition. 2019;62:25–31. PubMed

Winter JE, MacInnis RJ, Wattanapenpaiboon N, Nowson CA. BMI and all-cause mortality in older adults: a meta-analysis. Am J Clin Nutr. 2014;99(4):875–90. PubMed

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. PubMed PMC

Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531–2. PubMed

Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321–35. PubMed PMC

Batsis JA, Barre LK, Mackenzie TA, Pratt SI, Lopez-Jimenez F, Bartels SJ. Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999–2004. J Am Geriatr Soc. 2013;61(6):974–80. PubMed

Yang M, Jiang J, Hao Q, Luo L, Dong B. Dynapenic obesity and lower extremity function in elderly adults. J Am Med Dir Assoc. 2015;16(1):31–6. PubMed

Zibellini J, Seimon RV, Lee CM, Gibson AA, Hsu MS, Sainsbury A. Effect of diet-induced weight loss on muscle strength in adults with overweight or obesity—a systematic review and meta-analysis of clinical trials. Obes Rev. 2016;17(8):647–63. PubMed

Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364(13):1218–29. PubMed PMC

Simati S, Kokkinos A, Dalamaga M, Argyrakopoulou G. Obesity paradox: fact or fiction? Curr Obes Rep. 2023;12(2):75–85. PubMed

Wolk R, Bertolet M, Singh P, Brooks MM, Pratley RE, Frye RL, et al. Prognostic value of adipokines in predicting cardiovascular outcome: explaining the obesity paradox. Mayo Clin Proc. 2016;91(7):858–66. PubMed PMC

Bahat G, Kilic C, Ozkok S, Ozturk S, Karan MA. Associations of sarcopenic obesity versus sarcopenia alone with functionality. Clin Nutr. 2021;40(5):2851–9. PubMed

Ozkok S, Aydin CO, Sacar DE, Catikkas NM, Erdogan T, Bozkurt ME, et al. Sarcopenic obesity versus sarcopenia alone with the use of probable sarcopenia definition for sarcopenia: associations with frailty and physical performance. Clin Nutr. 2022;41(11):2509–16. PubMed

Bosello O, Vanzo A. Obesity paradox and aging. Eat Weight Disord. 2021;26(1):27–35. PubMed

WHO. Obesity and overweight. 9 June 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 10 Dec 2023.

National Center for Health Statistics. Health US. Normal weight, overweight, and obesity among adults aged 20 and over, by selected characteristics United States, selected years 1988–1994 through 2015–2018—Con. 2019. https://www.cdc.gov/nchs/data/hus/2019/026-508.pdf. Accessed 4 Dec 2023.

Carl Baker HOCL. Obesity Statistics. 12 January 2023. https://researchbriefings.files.parliament.uk/documents/SN03336/SN03336.pdf. Accessed 10 Dec 2023.

Malenfant JH, Batsis JA. Obesity in the geriatric population—a global health perspective. J Glob Health Rep. 2019;3:e2019045. PubMed PMC

WHO WHO. Ageing and health. 1 October 2022. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. Accessed 9 Dec 2023.

Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Hooper L, Kiesswetter E, et al. ESPEN practical guideline: clinical nutrition and hydration in geriatrics. Clin Nutr. 2022;41(4):958–89. PubMed

Waters DL, Ward AL, Villareal DT. Weight loss in obese adults 65years and older: a review of the controversy. Exp Gerontol. 2013;48(10):1054–61. PubMed PMC

Mathus-Vliegen EM, Obesity Management Task Force of the European Association for the Study of O. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts. 2012;5(3):460–83. PubMed

Uchitomi R, Oyabu M, Kamei Y. Vitamin D and sarcopenia: potential of vitamin D supplementation in sarcopenia prevention and treatment. Nutrients. 2020;12(10):3189. PubMed PMC

Lee PG, Jackson EA, Richardson CR. Exercise prescriptions in older adults. Am Fam Physician. 2017;95(7):425–32. PubMed

Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery. Circ Res. 2016;118(11):1844–55. PubMed PMC

Koliaki C, Liatis S, le Roux CW, Kokkinos A. The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr Disord. 2017;17(1):50. PubMed PMC

English WJ, DeMaria EJ, Hutter MM, Kothari SN, Mattar SG, Brethauer SA, et al. American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2020;16(4):457–63. PubMed

Iranmanesh P, Boudreau V, Ramji K, Barlow K, Lovrics O, Anvari M. Outcomes of bariatric surgery in elderly patients: a registry-based cohort study with 3-year follow-up. Int J Obes (Lond). 2022;46(3):574–80. PubMed

Mabeza RM, Mao Y, Maynard K, Lee C, Benharash P, Yetasook A. Bariatric surgery outcomes in geriatric patients: a contemporary, nationwide analysis. Surg Obes Relat Dis. 2022;18(8):1005–11. PubMed

Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther. 2015;9:1867–75. PubMed PMC

Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57: 101351. PubMed PMC

Iepsen EW, Torekov SS, Holst JJ. Liraglutide for type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13(7):753–67. PubMed

EMA EMA. Saxenda—summary of product characteristics. 16/04/2015 12/09/2023. https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf. Accessed 8 Dec 2023.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. PubMed

Rubino DC, Raquel & Kahan, Scott & Kushner, Robert & Wilding, John & Jepsen, Cecilie & Smolarz, Gabriel & Wyatt, Holly. Age no Impediment to Effective Weight Loss with Liraglutide 3.0 Mg: Data from Two Randomized Trials. In: Nutrology IJo, editor. XXI I Congresso Brasileiro de Nutrologia; 2018.

Perna S, Guido D, Bologna C, Solerte SB, Guerriero F, Isu A, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016;28(6):1251–7. PubMed

Bahat G, Ozkok S. How to adjust muscle mass while defining sarcopenia component of sarcopenic obesity: is body weight sufficient enough to represent body size? Aging Clin Exp Res. 2023;35(3):723–4. PubMed

Xiang J, Qin L, Zhong J, Xia N, Liang Y. GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes. 2023;16:2433–46. PubMed PMC

Tonoike M, Chujo D, Noda M. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes. Endocrinol Diabetes Metab. 2019;2(1): e00043. PubMed PMC

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, et al. Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial. Ann Intern Med. 2019;170(6):423–6. PubMed

Yoshida M, Yoshida A, Oh E, Yamamoto N, Sasaki E, Yoshida S, ET AL. 671-P: liraglutide possibly prevents progression of dementia in patients with type 2 diabetes. Diabetes. 2021;70(Supplement_1):671.

HANSSEN R, RIGOUX L, KUZMANOVIC B, IGLESIAS S, KRETSCHMER AC, SCHLAMANN M, et al. Liraglutide restores impaired associative learning in individuals with obesity. Nat Metab. 2023;5(8):1352–63. PubMed PMC

EMA EMA. Ozempic—summary of product characteristics. 21/02/2018 03/05/2023. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf. Accessed 8 Dec 2023.

Warren MCL, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B. Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1–5 trials. Diabetologia. 2017;60(Suppl 1):1–608. PubMed

Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B. Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1–5 trials. Diabetes Obes Metab. 2018;20(9):2291–7. PubMed PMC

Pratley RE, Aroda VR, Catarig AM, Lingvay I, Ludemann J, Yildirim E, et al. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open. 2020;10(11): e037883. PubMed PMC

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. PubMed

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sorrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–50. PubMed PMC

Yamada Y, Yabe D, Hertz CL, Horio H, Nakamura J, Nielsen AM, et al. Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: a subgroup analysis of the PIONEER 9 and 10 Japan trials. Diabetes Obes Metab. 2022;24(2):321–6. PubMed PMC

Uchiyama S, Sada Y, Mihara S, Sasaki Y, Sone M, Tanaka Y. Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes. J Clin Med Res. 2023;15(7):377–83. PubMed PMC

Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021;12(1):143–57. PubMed PMC

FDA USFaDA. Zepbound—full prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf. Accessed 8 Dec 2023.

EMA EMA. Mounjaro: summary of opinion (post authorisation). 2023. https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mounjaro-ii-07_en.pdf. Accessed 2 Jan 2024.

FDA USFaDA. Mounjaro—full prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf. Accessed 8 Dec 2023.

EMA EMA. Mounjaro—summary of product characteristics. 25/11/2022 26/10/2023. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf. Accessed 8 Dec 2023.

Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55. PubMed

Abdalla MA, Soyiri I, Atkin S, Sathyapalan T. Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: a pooled analysis of subgroups of SURPASS 1–5 trials. J Diabetol. 2023;14(2):65–73.

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. PubMed

Aronne L. ECO2023 NEWSLETTER: DAY THREE: new analysis shows improved body composition with tirzepatide is consistent across adult age groups with overweight or obesity. 2023. https://easo.org/eco2023-newsletter-day-three-new-analysis-shows-improved-body-composition-with-tirzepatide-is-consistent-across-adult-age-groups-with-overweight-or-obesity/. Accessed 1 Feb 2024.

Kiyosue A, Dunn JP, Cui X, Hickey A, Hirase T, Imaoka T, et al. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes Obes Metab. 2023;25(4):1056–67. PubMed

Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646–67. PubMed PMC

EMA EMA. Mysimba—summary of product characteristics. 15/04/2015. https://www.ema.europa.eu/en/documents/product-information/mysimba-epar-product-information_en.pdf. Accessed 4 Jan 2024.

Kim KK. Understanding the mechanism of action and clinical implications of anti-obesity drugs recently approved in Korea. Korean J Fam Med. 2019;40(2):63–71. PubMed PMC

Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51(3):293–313. PubMed

Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A review of the important role of CYP2D6 in pharmacogenomics. Genes (Basel). 2020;11(11):1295. PubMed PMC

Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10(1):14–30. PubMed PMC

FDA USFaDA. Contrave—full prescribing information. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. Accessed 10 Dec 2023.

Huecker MR, Smiley A, Saadabadi A. Bupropion. Treasure Island: StatPearls; 2024. PubMed

Bansal AB, Al Khalili Y. Orlistat. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Yasir Al Khalili declares no relevant financial relationships with ineligible companies. 2024.

EMA EMA. Xenical—summary of product characteristics. 2009. https://www.ema.europa.eu/en/documents/product-information/xenical-epar-product-information_en.pdf. Accessed 10 Dec 2023.

Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003;43(4):428–35. PubMed

MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003;37(4):510–2. PubMed

Humayun Y, Ball KC, Lewin JR, Lerant AA, Fulop T. Acute oxalate nephropathy associated with orlistat. J Nephropathol. 2016;5(2):79–83. PubMed PMC

Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61. PubMed

Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab. 2011;15(2):99–104. PubMed PMC

Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306–13. PubMed

Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235–42. PubMed

Kweder H, Eidi H. Vitamin D deficiency in elderly: risk factors and drugs impact on vitamin D status. Avicenna J Med. 2018;8(4):139–46. PubMed PMC

Bahat G, Ozkok S. The current landscape of pharmacotherapies for sarcopenia. Drugs Aging. 2024;41(2):83–112. PubMed

Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. 10.1038/s41366-024-01473-y. PubMed PMC

Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1): e2033457. PubMed PMC

Pedersen SD MP, Wharton S. Canadian Adult Obesity Clinical Practice Guidelines: Pharmacotherapy for Obesity Management. 2022. https://obesitycanada.ca/guidelines/pharmacotherapy/. Accessed 7 Dec 2023.

Coming of age: could obesity-related metabolic complications be treated by targeting senescent cells?